News
In nine studies (76 patients), the anti-IgE monoclonal antibody omalizumab (Xolair), given every 2-4 weeks at doses ranging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback